EDIT$3.49
$3.45
Chart
Performance
Key Stats
AI EDIT Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldEditas Medicine shows promise in gene editing technology but faces significant financial challenges and a highly competitive landscape. The current technical indicators are mixed, suggesting a cautious 'Hold' rating.
Thematic
Editas Medicine operates within the high-growth gene editing and genomic medicine sector. The increasing focus on personalized medicine and treatments for rare diseases provides strong thematic tailwinds.
Fundamental
Editas Medicine exhibits weak financial performance with consistent net losses and negative earnings per share. While revenue is growing, it remains insufficient to cover substantial operating expenses and R&D costs.
Technical
The stock is trading below key moving averages and shows mixed signals from oscillators. While there's some recent positive momentum, it faces resistance from its longer-term trend.
| Factor | Score |
|---|---|
| Genomic Medicine Advancements | 85 |
| Rare Disease Treatments | 80 |
| Competitive Landscape | 50 |
| Regulatory Pathway & Approval | 40 |
| Partnerships and Collaborations | 75 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 15 |
| Balance Sheet Health | 40 |
| Cash Flow | 20 |
| Earnings Per Share (EPS) | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 35 |
| Momentum | 60 |
| Support & Resistance | 45 |
| Volume | 40 |
| MACD | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Strong Short-Term Performance
The stock has shown significant gains over various short-term periods, with a 1-month performance of 37.28% and a year-to-date (YTD) performance of 138.93%.
Potential Value Based on Price-to-Sales
The Price-to-Sales (P/S) ratio of 3.3 (for 2023) and 3.5 (for 2023Q4) suggests potential value if revenue growth is sustained, though current TTM P/S is 7.4.
Bearish Points (9)
Consistent Net Losses
The company has consistently reported net losses, with a net income of -$237.09 million in 2024 and -$153.22 million in 2023, indicating a lack of profitability.
Negative Net Profit Margin
Net profit margins are significantly negative across all reported periods (e.g., -733.7% in 2024Q4), highlighting a fundamental lack of profitability.
Calendar
August 2025
7
Next Earnings Date
H: $-0.29
A: $-0.37
L: $-0.44
H: 5.00M
A: 1.80M
0Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Seasonals
Price Target
3.38 USD
The 39 analysts offering 1 year price forecasts for EDIT have a max estimate of 5.00 and a min estimate of 1.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in CRISPR gene editing, with a leading clinical pipeline, particularly for ex-vivo applications like exa-cel (CRISPR/Cas9-based therapy for sickle cell disease and beta thalassemia).
Weight: 92
Direct competitor in CRISPR gene editing, focusing on in vivo CRISPR/Cas9 applications, including a leading program for transthyretin amyloidosis.
Weight: 88
Pioneer in base editing, a next-generation CRISPR technology that offers precise single-base changes without double-strand breaks, directly competing for certain disease targets with traditional CRISPR.
Weight: 85
Developing prime editing, an advanced gene-editing technology that allows for a wider range of precise edits (insertions, deletions, and all 12 types of point mutations) with high accuracy and fewer off-target effects.